SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome
- 1 April 2021
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 137 (13), 1835-1838
- https://doi.org/10.1182/blood.2020008536
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology GroupBlood, 2017
- Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemiaOncotarget, 2016
- EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implicationsBlood, 2016
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2014
- Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusionHaematologica, 2013
- Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALLBlood, 2013
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic LeukemiaCancer Cell, 2012
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2009